{"id":"W2149388786","doi":"10.1056/nejmoa1007432","title":"Apixaban in Patients with Atrial Fibrillation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2420,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute","funders":"Bayer Vital; St. Jude Medical; Cilag; Astellas Pharma; Sanofi; Hamilton Health Sciences; GlaxoSmithKline; Institut de Cardiologie de Montréal; Servier; McMaster University; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atrial fibrillation; Apixaban; Cardiology; Internal medicine; Medicine; Warfarin; Rivaroxaban","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04872069212477084,"score_gpt":0.2871827491352683,"score_spread":0.2384620570104975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}